Schedule 13G ownership disclosure
X4 Pharmaceuticals Inc
Common Stock, par value $0.001 per share · CUSIP: 98420X202
Event date: 2025-08-12
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Deep Track Capital, LP
Shares: 2,366,995.00 · Class: 9.99%
- Deep Track Biotechnology Master Fund, Ltd.
Shares: 2,366,995.00 · Class: 9.99%
- David Kroin
Shares: 2,366,995.00 · Class: 9.99%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001172661-25-003668
- Form type
- SCHEDULE 13G
- Filer
- Deep Track Capital, LP
- CIK
- CIK 1856083
- Filed
- Aug 19, 2025
- Reporting period
- Aug 12, 2025
- Description
- Schedule 13G beneficial ownership